A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Trial Profile

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs OTX 101 (Primary)
  • Indications Keratoconjunctivitis sicca
  • Focus Registrational; Therapeutic Use
  • Acronyms Emerald
  • Sponsors Ocular Technologies
  • Most Recent Events

    • 15 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 04 Jan 2017 According to a Sunesis Pharmaceuticals Media Release, additional significant findings from this trial will be shared at upcoming medical conferences.
    • 04 Jan 2017 Primary endpoint has been met. (Tear Production), as reported in a Sunesis Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top